Latest Avastin Stories
In patients with moderate or worse vision loss at baseline, those treated with EYLEA gained, on average, an additional full line or more on an eye chart when compared to those treated with alternative
Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab THOUSAND OAKS, Calif., Jan.
ReportsnReports.com adds "Colorectal Cancer - Japan Drug Forecast and Market Analysis to 2023" to its store.
RnRMarketResearch.com adds "Avastin and Cyramza (Colorectal Cancer) - Forecast and Market Analysis to 2023" to its store.
TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response
Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
CAMBRIDGE, Mass., Feb.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.